Novo Nordisk A/S

NVO remains in a clear Stage 2 advancing regime with price above rising EMAs and the 50 DMA, but it is currently extended with extreme overbought conditions. Medium-term bias stays bullish, yet short-term timing is neutral. We defer new entries and await a pullback into the rising EMA support zone to be absorbed before committing. Long-term downtrend continues to anchor broader caution.

• ↑Obesity care sales +22% to DKK 9.2bn; 50% more patients served.
• ↑Oral Wegovy pill uptake >2× any prior anti-obesity US launch.
• ↓GLP-1 segment market share declined 9% amid Eli Lilly competition.